Predictive diagnostic and/ or prognostic biomarkers obtained from routine blood biochemistry in patients with solitary intracranial tumor
Abstract
Background: Radiological and/or laboratory tests may be sometimes inadequate to differentiate glioblastoma from metastatic brain tumors. This study aimed to find biomarkers that distinguish between glioblastoma and metastatic brain tumor by using blood biochemistry analysis results evaluated preoperatively in patient with solitary intracranial tumor.
Methods: Patients admitted to neurosurgery clinic between January 2015 and September 2018 were included in this study and they were divided into two groups called GLIOMA (n=12) and METASTASIS (n=17). Patients’ data consisted of age, gender, Glasgow Coma Scale scores, length of stay in hospital, Glasgow Outcome Scale (GOS) scores and histopathological examination reports was recorded. Hemoglobin level, count results of the leukocyte, neutrophil, lymphocyte, monocyte, eosiophil, basophil and platelet, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio results, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) levels were evaluated preoperatively.
Results: The CRP levels of METASTASIS group (14.31±2697) were significantly higher than those of GLIOMA group (2.39±4.99). CRP was 82% sensitive and 75% specific in distinguishing the metastatic brain tumor from glioblastoma if CRP level value was >5.5 mg/dL. A positive correlation was determined between GOS score and hemoglobin level and between ESR and CRP values. A negative correlation was found between GOS score and ESR level and between GOS score and duration of hospitalization.
Conclusion: It was considered that CRP level values could be a predictive biomarker in distinguishing metastatic brain tumor from glioblastoma; and ESR, CRP, hemoglobin levels and duration of hospital stay could be prognostic biomarkers in predicting short-term prognosis of patients with intracranial tumor.
References
REFERENCES
Bauer AH, Erly W, Moser FG, Maya M, Nael K. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion. Neuroradiology 2015; 57(7): 697-703.
Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007; 28(6): 1078-84.
Giese A, Westphal M. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol 2001; 127(4): 217-25.
Mukundan S, Holder C, Olson JJ. Neuroradiological assessment of newly diagnosed glioblastoma. J Neurooncol 2008; 89(3): 259-69.
Nijaguna MB, Schröder C, Patil V, Shwetha SD, Hegde AS, Chandramouli BA, et al. Definition of a serum marker panel for glioblastoma discrimination and identification of interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein. J Proteomics 2015; 128: 251-61.
Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res 2014; 34(1): 339-47.
Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009; 9(7): 695-707.
Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2(7872): 81-4.
McMillan T, Wilson L, Ponsford J, Levin H, Teasdale G, Bond M. The Glasgow Outcome Scale - 40 years of application and refinement. Nat Rev Neurol 2016; 12(8): 477-85.
Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4(11): 839-49.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30(7): 1073-81.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28(16): 2719-26.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291(5): 585-90.
Juan H, Qijun W, Junlan L. Serum CRP protein as a differential marker in cancer. Cell Biochem Biophys 2012; 64(2): 89-93.
Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009; 32(5): 471-82.
Bunevicius A, Radziunas A, Tamasauskas S, Tamasauskas A, Laws ER, Iervasi G, et al. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients. J Neurooncol 2018; 138(2): 351-8.
Blaylock RL. Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis. Surg Neurol Int 2013; 4: 15.
Galvão RP, Zong H. Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression. Curr Pathobiol Rep 2013; 1(1): 19-28.
Weiss JF, Morantz RA, Bradley WP, Chretien PB. Serum acute-phase proteins and immunoglobulins in patients with gliomas. Cancer Res 1979; 39(2 Pt 1): 542-4.
Kataki A, Skandami V, Memos N, Nikolopoulou M, Oikonomou V, Androulis A, et al. Similar immunity profiles in patients with meningioma and glioma tumors despite differences in the apoptosis and necrosis of circulating lymphocyte and monocyte populations. J Neurosurg Sci 2014; 58(1): 9-15.
Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61(9): 824-33.
Copyright (c) 2020 Ulas Yuksel
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.